Centene Q3 revenue tops estimates on Medicare growth
CNC•Centene reported Q3 revenue of $50.65 billion and adjusted EPS of $0.58, beating analyst estimates of $47.11 billion and $0.10, respectively. It raised 2026 adjusted diluted EPS guidance to greater than $5.20 and lowered its health benefits ratio outlook to 90.4%-91.1%.
1. Quarterly results
Centene said Q3 revenue rose, driven by premium yield and membership growth in its Medicare Prescription Drug Plan business. The company reported revenue of $50.65 billion, adjusted EPS of $0.58 and a loss per share of $0.14.
2. Updated 2026 outlook
Centene raised its 2026 GAAP diluted EPS guidance to greater than $3.46 and adjusted diluted EPS guidance to greater than $5.20. It lowered its 2026 health benefits ratio guidance range to 90.4%-91.1%; the company cited improved Marketplace pricing and risk transfer, along with cost management, as factors affecting its results.
